SCHEMBL972679

SCHEMBL972679

Cc1cc(NC(=O)c2cc(Cl)ccc2NS(=O)(=O)c2ccc(Cl)cc2)ccc1S(=O)(=O)N1Cc2ccccc2C1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR27 Q9NS67 9/20 0.55
SLC10A6 Q3KNW5 2/20 0.52
SLC10A2 Q12908 1/20 0.52
SLC10A1 Q14973 1/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
LMNA P02545 3/20 0.51
HTT P42858 3/20 0.51
MAPT P10636 3/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HPGD P15428 1/20 0.51
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
KCNA5 P22460 1/20 0.48
PTGES2 Q9H7Z7 1/20 0.47
AVPR2 P30518 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL492077 0.88 ALDH1A1 (0.61) GPR27SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL491702 0.86 SLC10A6 (0.52) GPR27SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL491818 0.86 CNR2 (0.58) GPR27SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL491915 0.84 SLC10A6 (0.50) GPR27SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL491913 0.84 SLC10A6 (0.50) GPR27SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL27816207 0.80 LMNA (0.42) GPR27KMT2ALMNAHTTMAPT
SCHEMBL6754585 0.77 SLC10A6 (0.81) GPR27SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL492042 0.77 SLC10A2 (0.61) GPR27SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL5119315 0.76 SLC10A6 (0.65) GPR27SLC10A6SLC10A2SLC10A1MEN1
SCHEMBL28747315 0.76 SLC10A6 (0.48) GPR27SLC10A6SLC10A2SLC10A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518998-B2 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-08-27 US disclosed
US-20110021505-A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-01-27 US disclosed
EP-2207541-A1 USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN Sanofi-Aventis Deutschland GmbH (DE) 2010-07-21 EP disclosed
WO-2009043495-A1 USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021505-A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SCN1A, SCN2A, CACNA1A GPR27 1930/4885SLC10A6 192/4885SLC10A2 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.